In addition, if miR-618 exhibits similar inhibition effects on the PI3K/Akt pathway or/and on TGF-β in the patients with mCC, it could explain that miR-618 acts as tumor-suppressor miRNA in patients and its low levels imply a progression of the disease. The gene discussed is TGFB1; the disease is neoplasm.